Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Big push up any moment. They are searching for stock. No float at all.
Jimzi - I was trying to buy with Hargreaves Lansdowne. I was trying to get the 11.5p, but it's gone for now.
Got rejected for 25k!!!
Maybe try a fill or kill - as I'm with IG and rsp - I don't have that facility but sometimes it worked in the past
I just tried to add 55,000 shares @ 11.5p. It's gone straight to NT. It won't even allow me to add 15,000.
Who said 27p
Pleasures mine - they were a very eloquent and compelling couple of posts - EV £3 is farcical when you read them.
Well I took note as well. The simple truth is that, after 3rd party validation should it materialise, the value of the heart tech to the industry runs to 3 figure millions. One daren't even attempt to work out what it could mean in price per share terms.
Good to see some familiar names popping up. All the best if you just bought in today.
Thanks Jimzi. I’m glad someone took note :D
Thanks Popeye.Yes looks really interesting.Atb.Caio.
Baserite - Welcome aboard. This is currently as cheap as chips. Well done on buying in. Atb Popeye.
It's at the placing price!
Typo-consternation
Taken a small position here.Interesting stock.Looks like it may slide to around placing but that isn’t going to cause me any consideration.Who knows, may surge forward over the coming week.Atb all lth’s and good luck.
Just picked up 100k not showing yet
RICK YOUR A BIGGER MAN WHEN u walk away dont take the bait
Cando66, As you said yesterday, 50% up by midweek? lol where are you now?
Is there going to be a set to
Love a good punch up
Just to let everyone know that Steel did in fact offer me out and I have not engaged, so yes I am a big 🐱 for not wanting to fight him. Hope that makes you feel better Steel. Now get on with your miserable life.
Amati sold, it's not because of redemptions. That's because the shares are not held in the open-ended fund but in the permanent capital VCT compliant AIM investment trust, AMAT.
Re: the strategic review announced by AMAT last month it's a good thing in my opinion. That's because the trust has to operate under v onerous restrictions in order to preserve VCT status. For instance, they cannot buy shares in the open market. Purchases can only be made at an IPO or at a subsequent placing, which means they cannot buy more of a share simply because the price has fallen and they reckon it's good value. Similarly, they cannot buy a share they have previously sold. Imagine investing in that way - it's hard enough making money on AIM, without having to navigate these VCT compliant handicaps additionally. I'm therefore not in the least surprised that AMAT has been such a poor performer ; this financial instrument gives rise to a sparkling unique opportunity to get in after all the hard work (£) has been done but they can’t buy back.
Amati subscribed for 8% (then around 1.7M shares) at 120p in the Dec 20 placing.
They dumped over half at prices from 80p downwards after the 510k FDA setback in 2021. They hold 775k now which, after the last 11p placing leaves them at 1.24% so not declarable if they sell the rest. I don’t think they will. Little point.
I can't find Amati's buy in notification but I think it was higher than 50p. They'd been reducing for a while, but are out now. We haven't had any notifications in months. 8-9p is likely a historic bottom.
4 years of cash, plenty in the pipeline.
Traders will trade, causing the low liquidity to play a part in daily share price movements, but fundamentally even if you bought at 14p, this is still an obvious bargain. Simply wall street puts fair value at 79p.
Excellent summary of the massive and very realistic potential and thank the Lord, a post about the company and cos and not bickering / name calling. As you say, invest in the company not the hourly price.
I’m not here for the hourly movements in share price but hold for the bigger picture. So here’s a bit of the artwork on display:
Edwards Life Sciences is the biggest player in the heart valve TAVR market, worth multiple billions. They are one of only 4 or 5 majors worldwide in the heart valves business, all are American except Corcym which is by far the smallest of them.
One of these has signed an MTA to look at RUA’s new composite material which, based on its own benchtop trials, it claims is considerably stronger, tear resistant yet thinner and flexible, ideal for TAVR and all improvements over current technologies which rely on animal tissue sourced from cows in Australia and New Zealand, the only BSE-free herds in the world. You can see why the majors will eventually want to develop something new that doesn’t rely on a risky supply chain such as these animals. If BSE invaded Australia, these majors would freak out.
In December, Edwards spun off its critical care unit to concentrate on heart valves. That’s a big statement from the 800 pound gorilla in the heart valve room.
See this link.
https://www.forbes.com/sites/joecornell/2023/12/19/edwards-lifesciences-to-spin-off-critical-care-unit-in-2024/
I particularly noted this:
“The company’s decision to spin off the Critical Care segment signifies a strategic shift, aiming to streamline operations and redirect attention towards the TAVR segment. TAVR segment not only promises high growth but also offers lucrative profit margins. This strategic move enables a focused approach to capitalize on broader opportunities within the realm of heart devices while fostering innovation through investments in cutting-edge technologies.”
We have not been told Edwards is the MTA partner but it’s possible. In any case, RUA has said it is actively seeking other partners for an MTA. That’s either a sign of intent to target the whole industry or a warning to the current partner to get on with testing while it has a headstart!
RUA is so small in relation to the majors, I’m amazed one of them hasn’t used some coins from behind the sofa cushions to hoover this possible technology up. However, maybe this new material might trigger some action.
All speculation on my part but it makes sense to me and is mainly why I hold a big lump of these. Plus, they have a small but profitable business in contract manufacturing that alone backs up the current market cap.